

KOLOREKTAL KANSERLERDE PET/BT VE PET/MR GÖRÜNTÜLEME

12. BÖLÜM

Banu KIRTILOĞLU¹


Fatih BATI²

ÖZET

Kolorektal kanserler, yıllık yaklaşık 2 milyon vaka insidansı ile erkek ve kadınlarda en sık görülen kanserlerin başında gelmektedir. Erken tanı ve tedavisi çok önemlidir bu nedenle çeşitli tarama programları da geliştirilmiştir. PET/BT ve PET/MR görüntüleme, son yıllarda özellikle onkoloji alanına çok önemli katkılar sağlamakta, kanserlerin tanısı, evrelemesi, yeniden evrelemesi, tedaviye yanıtın değerlendirilmesi ve takiplerinden sıklıkla başvuru alan bir modalite haline gelmiştir. Kolorektal kanserlerin karaciğer metastazlarında da radyoembolizasyon tedavisi ile Nükleer Tıp sadece tanıda değil tedavide de önemli bir yeri olduğunu bilimsel çalışmalarla ispatlamıştır. Kolorektal kanserlerin primer tanısında ileri evrelerde, nodal evrelemede, hepatik ve ekstrahepatik metastazların tespitinde PET/BT'nin önemli katkıları mevcuttur.

¹ Uzm. Dr. Banu KIRTILOĞLU, Sağlık Bilimleri Üniversitesi Samsun Eğitim ve Araştırma Hastanesi Nükleer Tıp AD bkirtiloglu@yahoo.com

² Uzm. Dr. Fatih BATI, Sağlık Bilimleri Üniversitesi Samsun Eğitim ve Araştırma Hastanesi, Nükleer Tıp AD drfatihbati@gmail.com



Şekil 9. Rektum kanserli 59 yaşında bir erkek. FDG PET/BT, neoadjuvan kemoradyasyon tedavisine (B, ok) mükemmel bir metabolik yanıt ile FDG duyarlı bir primer tümörü (A, ok) göstermektedir. Takip görüntülerinde (C, ok) anal bölgede, radyoterapi sonrası fistül oluşumunun neden olduğu inflamatuvar süreci düşündüren, fokal FDG tutulumunun arttığı izlendi⁽²⁸⁾.

KAYNAKLAR

- Özkan M. Ö. (2015). Kolorektal Kanserlerin Evreleme ve Tedavi Takibinde PET/BT'nin Rolü. Aydın: Uzmanlık Tezi
- Dahmarde H, Parooie F, Salarzaei M. Is 18F-FDG PET/CT an Accurate Way to Detect Lymph Node Metastasis in Colorectal Cancer: A Systematic Review and Meta-Analysis. *Contrast Media Mol Imaging*. 2020;2020:5439378. Published 2020 Jul 18. doi:10.1155/2020/5439378
- Jonathan D. Berry, Gary J. R. Cook, Positron emission tomography in oncology, *British Medical Bulletin*, Volume 79-80, Issue 1, June 2006, Pages 171–186, <https://doi.org/10.1093/bmb/ldl013>
- Mehmet SAĞIROĞLU. *Türkiye Klinikleri J Med Oncol-Special Topics*. 2013;6(3):26-8
- Engelen S, Beets G, Beets – Tan R, Role of Preoperative Local and Distant Staging in Rectal Cancer, *Onkologie*, 2007, 30:141 – 145
- M. Rodríguez-Fraile, M.P. Cózar-Santiago, A. Sabaté-Llobera, FDG PET/TC en el cáncer colorrectal, *Revista Española de Medicina Nuclear e Imagen Molecular*, Volume 39, Issue 1, January–February 2020, Pages 57-66
- Esteves FP, Schuster DM, Haklar RK. Gastrointestinal tract malignancies and positron emission tomography: An overview. *Semin Nucl Med*, 2006; 36:169-181
- Dahmarde H, Parooie F, Salarzaei M. Is 18F-FDG PET/CT an Accurate Way to Detect

- Lymph Node Metastasis in Colorectal Cancer: A Systematic Review and Meta-Analysis. *Contrast Media Mol Imaging*. 2020;2020:5439378. Published 2020 Jul 18. doi:10.1155/2020/5439378
9. Falconer R, Connor S, Balasingam A, Eglinton T. Does positron emission tomography/computed tomography change management in colorectal cancer? *ANZ J Surg*. 2018;88(4):E248-E251. doi:10.1111/ans.13798
 10. Lee JW, Kim SK, Lee SM, Moon SH, Kim TS. Detection of hepatic metastases using dual-time-point FDG PET/CT scans in patients with colorectal cancer. *Mol Imaging Biol*. 2011;13(3):565-572. doi:10.1007/s11307-010-0394-x
 11. Ramos E, Martínez L, Gámez C, et al. Utilidad de la PET-TC en la estadificación previa a la cirugía por metástasis hepáticas de carcinoma colorrectal [Use of PET-CT in pre-surgical staging of colorectal cancer hepatic metastases]. *Cir Esp*. 2008;84(2):71-77. doi:10.1016/s0009-739x(08)72137-7
 12. Yeoh E, Miles K. Simultaneous positron emission tomography and magnetic resonance imaging for the detection and characterisation of liver lesions in patients with colorectal cancer: A pictorial review. *J Med Imaging Radiat Oncol*. 2019;63(5):624-629. doi:10.1111/1754-9485.12936
 13. Queiroz MA, Ortega CD, Ferreira FR, Nahas SC, Cerri GG, Buchpiguel CA. Diagnostic accuracy of FDG-PET/MRI versus pelvic MRI and thoracic and abdominal CT for detecting synchronous distant metastases in rectal cancer patients [published online ahead of print, 2020 Jun 20]. *Eur J Nucl Med Mol Imaging*. 2020;10.1007/s00259-020-04911-x. doi:10.1007/s00259-020-04911-x
 14. Falconer R, Connor S, Balasingam A, Eglinton T. Does positron emission tomography/computed tomography change management in colorectal cancer? *ANZ J Surg*. 2018;88(4):E248-E251. doi:10.1111/ans.13798
 15. Milardovic R, Beslic N, Sadija A, Ceric S, Bukvic M, Dzananovic L. Role of 18F-FDG PET/CT in the Follow-up of Colorectal Cancer. *Acta Inform Med*. 2020;28(2):119-123. doi:10.5455/aim.2020.28.119-123
 16. Gary A. Ulaner. (2019). *Fundamentals of Oncologic PET/CT*. Elsevier
 17. Akin EA, Qazi ZN, Osman M, Zeman RK. Clinical impact of FDG PET/CT in alimentary tract malignancies: an updated review. *Abdom Radiol (NY)*. 2020;45(4):1018-1035. doi:10.1007/s00261-020-02447-0
 18. Mafone AM, Marzola MC, Capirci C, Colletti PM, Rubello D (2015) Value of (18) F-FDG PET for Predicting Response to Neoadjuvant Therapy in Rectal Cancer: Systematic Review and MetaAnalysis. *AJR American journal of roentgenology* 2015;204: 1261-1268. 10.2214/AJR.14.13210.
 19. Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, Gambhir SS (2000) A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. *Journal of nuclear medicine : ofcial publication, Society of Nuclear Medicine* 41 (7):1177-1189
 20. Sokolović E, Cerić T, Cerić Š, et al. The Prognostic Value of SUVmax of 18F-FDG PET/CT in Patients with Metastatic Colorectal Cancer. *Acta Med Acad*. 2020;49(1):1-8. doi:10.5644/ama2006-124.278
 21. Nemeth Z, Wijker W, Lengyel Z, Hitre E, Borbely K. Metabolic Parameters as Predictors for Progression Free and Overall Survival of Patients with Metastatic Colorectal Cancer [published online ahead of print, 2020 Jul 13]. *Pathol Oncol Res*. 2020;10.1007/s12253-020-00865-5. doi:10.1007/s12253-020-00865-5
 22. Arslan E, Aksoy T, Gürsu RU, Dursun N, Çakar E, Çermik TF. The Prognostic Value of

- 18F-FDG PET/CT and KRAS Mutation in Colorectal Cancers. *Mol Imaging Radionucl Ther.* 2020;29(1):17-24. doi:10.4274/mirt.galenos.2019.33866
23. Ogawa S, Itabashi M, Kondo C, Momose M, Sakai S, Kameoka S. Prognostic Value of Total Lesion Glycolysis Measured by 18F-FDG-PET/CT in Patients with Colorectal Cancer. *Anticancer Res.* 2015;35(6):3495-3500.
24. Roh SH, Jung S-A, Kim S-E, Kim H-I, Lee MJ, Tae CH, Choi JY, Shim K-N, Jung H-K, Kim TH, Yoo K, Moon IH, Kim BS (2012) The Clinical Meaning of Benign Colon Uptake in (18)F-FDG PET: Comparison with Colonoscopic Findings. *Clinical Endoscopy* 45 (2):145-150. <https://doi.org/10.5946/ce.2012.45.2.145>
25. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF (1981) Metformin kinetics in healthy subjects and in patients with diabetes mellitus. *British Journal of Clinical Pharmacology* 12 (2):235-246
26. Schmidt E, Nehra V, Lowe V, Oxentenko AS (2016) Clinical significance of incidental [18 F]FDG uptake in the gastrointestinal tract on PET/CT imaging: a retrospective cohort study. *BMC Gastroenterology* 16:125. <https://doi.org/10.1186/s12876-016-0545-x>
27. Gary A. Ulaner. (2019). *Fundamentals of Oncologic PET/CT*. Elsevier
28. Mohsen B., Alireza R., Ken H. (2017). *PET/CT in Cancer*. Elsevier
29. Audollent R, Eveno C, Dohan A, et al. Pitfalls and mimickers on (18)F-FDG-PET/CT in peritoneal carcinomatosis from colorectal cancer: An analysis from 37 patients. *J Visc Surg.* 2015;152(5):285-291. doi:10.1016/j.jvisurg.2015.06.003
30. Gourd E. New radiotracer shows impressive diagnostic potential. *Lancet Oncol.* 2019;20(7):e353. doi:10.1016/S1470-2045(19)30422-X
31. Nakajo M, Nakajo M, Kajiya Y, et al. Diagnostic performance of (1)(8)F-fluorothymidine PET/CT for primary colorectal cancer and its lymph node metastasis: comparison with (1)(8)F-fluorodeoxyglucose PET/CT. *European Journal of Nuclear Medicine and Molecular Imaging.* 2013;40(8):1223-1232.
32. Dietz DW, Dehdashti F, Grigsby PW, et al. Tumor hypoxia detected by positron emission tomography with 60Cu- ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. *Diseases of the Colon and Rectum.* 2008;51(11):1641-1648.
33. Toucheffeu Y, Bailly C, Frampas E, et al. Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study [published online ahead of print, 2020 Aug 21]. *Eur J Nucl Med Mol Imaging.* 2020;10.1007/s00259-020-04989-3. doi:10.1007/s00259-020-04989-3
34. van Roekel C, Bastiaannet R, Smits MLJ, et al. Dose-effect relationships of holmium-166 radioembolization in colorectal cancer [published online ahead of print, 2020 Jun 26]. *J Nucl Med.* 2020;jnumed.120.243832. doi:10.2967/jnumed.120.243832
35. Ye Y, Liu T, Lu L, et al. Pre-operative TNM staging of primary colorectal cancer by (18)F-FDG PET-CT or PET: a meta-analysis including 2283 patients. *Int J Clin Exp Med.* 2015;8:21773-21785.
36. Lee JH, Lee MR. Positron emission tomography/computed tomography in the staging of Colon Cancer. *Ann Coloproctol.* 2014;30:23-27.
37. Ruers TJ, Wiering B, van der Sijp JR, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. *J Nucl Med.* 2009;50:1036-1041.

38. Lee JY, Yoon SM, Kim JT, et al. Diagnostic and prognostic value of preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography for colorectal cancer: comparison with conventional computed tomography. *Intest Res.* 2017;15(2):208-214. doi:10.5217/ir.2017.15.2.208
39. Maffione AM, Rubello D, Caroli P, Colletti PM, Matteucci F. Is It Time to Introduce PET/CT in Colon Cancer Guidelines? *Clin Nucl Med.* 2020;45(7):525-530. doi:10.1097/RLU.0000000000003076